The present invention relates to a method for treating allergic diseases
such as asthma, comprising administering a tyrosine kinase inhibitor to a
human in need of such treatment, more particularly a non-toxic, selective
and potent c-kit inhibitor. Preferably, said inhibitor is unable to
promote death of IL-3 dependent cells cultured in presence of IL-3.